Emrok

Wockhardt Ltd. is the 1st Indian company to launch Novel chemical entity in antiobiotics space with Emrok & Emrok O. 

Indian drug regulator, DCGI has approved Wockhardt’s 2 new antibiotics, EMROK (IV) and EMROK O (Oral), for acute bacterial skin and skin structure Infections including diabetic foot infections and concurrent bacteraemia based on the Phase 3 study involving 500 patients in 40 centres across India. The new drug targets superbug like Methicillin resistant Staphylococcus aureus (MRSA), which is a leading cause of rising antimicrobial resistance (AMR).

EMROK is an intravenous formulation of arginine salt of Levonadifloxacin equivalent to 800 mg of Levonadifloxacin. EMROK O is an oral formulation of mesylate salt of Alalevonadifloxacin (prodrug of Levonadifloxacin) equivalent to 500 mg of Alalevonadifloxacin.

Buy Online Prescribing Information